Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to -$434.8 million.

  • Avalo Therapeutics' Retained Earnings fell 2982.11% to -$434.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$434.8 million, marking a year-over-year decrease of 2982.11%. This contributed to the annual value of -$370.3 million for FY2024, which is 1048.21% down from last year.
  • According to the latest figures from Q3 2025, Avalo Therapeutics' Retained Earnings is -$434.8 million, which was down 2982.11% from -$404.2 million recorded in Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Retained Earnings ranged from a high of -$208.5 million in Q1 2021 and a low of -$456.4 million during Q1 2024
  • Over the past 5 years, Avalo Therapeutics' median Retained Earnings value was -$321.7 million (recorded in 2023), while the average stood at -$324.1 million.
  • Per our database at Business Quant, Avalo Therapeutics' Retained Earnings tumbled by 5397.94% in 2021 and then skyrocketed by 1599.65% in 2025.
  • Over the past 5 years, Avalo Therapeutics' Retained Earnings (Quarter) stood at -$262.2 million in 2021, then dropped by 15.89% to -$303.8 million in 2022, then fell by 10.31% to -$335.1 million in 2023, then decreased by 10.48% to -$370.3 million in 2024, then fell by 17.43% to -$434.8 million in 2025.
  • Its Retained Earnings was -$434.8 million in Q3 2025, compared to -$404.2 million in Q2 2025 and -$383.4 million in Q1 2025.